Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Burke Thomas Barrett Acquires 10,000 Shares of Stock

Pulse Biosciences, Inc. (NASDAQ:PLSEGet Free Report) CEO Burke Thomas Barrett acquired 10,000 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 20th. The shares were bought at an average price of $8.56 per share, for a total transaction of $85,600.00. Following the transaction, the chief executive officer now owns 10,000 shares of the company’s stock, valued at approximately $85,600. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Pulse Biosciences Stock Down 3.4 %

Shares of PLSE opened at $11.53 on Thursday. Pulse Biosciences, Inc. has a 52-week low of $3.78 and a 52-week high of $13.62. The stock has a fifty day simple moving average of $8.01 and a two-hundred day simple moving average of $8.67. The company has a market capitalization of $636.69 million, a PE ratio of -14.74 and a beta of 1.73.

Pulse Biosciences (NASDAQ:PLSEGet Free Report) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.21) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after acquiring an additional 189,227 shares during the last quarter. Griffin Asset Management Inc. raised its position in Pulse Biosciences by 15.7% in the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after purchasing an additional 40,700 shares during the period. Inspire Investing LLC boosted its position in shares of Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after buying an additional 10,039 shares during the period. PNC Financial Services Group Inc. acquired a new stake in shares of Pulse Biosciences in the fourth quarter valued at $242,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Pulse Biosciences in the 1st quarter valued at $88,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Featured Stories

Insider Buying and Selling by Quarter for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.